Adebrelimab (PD-L1 inhibitor)
DZQH-KYLLFS-25-19
Phase 2 small_molecule active
Quick answer
Adebrelimab (PD-L1 inhibitor) for Pancreatic Cancer Metastatic is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Pancreatic Cancer Metastatic
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active